

| Pharmacy Name: | Phone: |
|-----------------------------|--------|
| Address: | Fax: |
| City/State/Zip [.] | Email: |

| Gastroenterology Referral Form | | | | | | | | | |
|---|---|---|----------------------|--------------------------------------|----------------------------|----------------------|---------|--|--|
| PATIENT | **PLEASE ATTACH COPIES OF INSURANCE CARDS (FRONT AND BA | | | | CK)** | | | | |
| Last Name: | First Name: | | DOB: | | Practice: | | | | |
| Address: | | | | | Address: | | | | |
| City: | State: | Zip: | Sex: | M F | City: Sta | ate: Zi _l | p: | | |
| Phone: | | SSN# | | | Prescriber Name: | | | | |
| Insurance Information | | | | | Prescriber NPI: | | | | |
| Insurance Plan: Insurance Plan: | | | Nurse/Key Contact: | | | | | | |
| Policy # | | Policy # | | Phone: | | | | | |
| Plan I.D. # | Plan I.D. # | | Fax: Email: | | | | | | |
| Diagnosis & Clinical Information | | | | | | | | | |
| **Please Attach Clinical/Progress Notes, Labs, Test, Supporting Primary Diagnosis** | | | | | | | | | |
| Crohn's Disease Diagnosis code: | | | TB/PPD Test: | TB/PPD Test: Positive Negative Date: | | | | | |
| Ulcerative (| | nosis code: | | | | | | | |
| Other: Allergies: | | | Allergies: | es: | | | | | |
| | | | | | | | | | |
| Currently received and/or prior filed therapies: | | | | | | | | | |
| Length of treatm | | | Height: | weign | τ: | | | | |
| Length of treatment: Site of Care: Home | | | Home | AIC Othe | r: | | | | |
| | | Drescriptio | on Informati | on | | | | | |
| Medication | Dose/Strength | Prescription | Directions | | | | Refills | | |
| | | INITIAL: Infuse 200mg | | than aver | y 9 wooks thoroafter | | | | |
| Entyvio (vedolizumab) | 300mg vial | INITIAL: Infuse 300mg IV at week 0, 2, 6, then every 8 weeks thereafter | | | | | | | |
| (vedolizumab) | | MAINTENANCE: Infuse | 300mg IV every _ | V | veeks | | | | |
| Infliximab | | INITIAL: Infuse | mg/kg IV at we | eek 0, 2, 6, | then every 8 weeks therea | fter | | | |
| (Inflectra) | | MAINTENANCE: Infuse mg/kg IV every weeks | | | | | | | |
| (Remicade) | 100mg vial | Other | | | | | | | |
| (Avsola) | | Pharmacist will round to the nearest 100mg Give exact dose (do NOT round) | | | | | | | |
| (Renflexis) | | | | <u> </u> | | , | | | |
| Stelara | 130 mg / 26ml vial | INITIAL: Weight based dosing, infuse IV | | | | | | | |
| (ustekinumab) | | 55kg or less: 260mg (2 vials) 55kg to 85kg: 390mg (3 vials) Greater than 85kg: 520 mg (4 vials) | | | | | | | |
| | 90mg (2x 45mg vials) | | | | dose, then every 8 weeks t | hereafter | | | |
| | | | | | | | | | |
| Clorizi | | INITIAL: Infuse 600mg/ | /10mL IV at week | 0. 4. and 8 | | | _ | | |
| Skyrizi (risankizumab) | 600mg / 10 ml vial | MAINTENANCE: Inject 360mg/2.4ml SQ via injector at week 12, then every 8 weeks thereafter | | | | | | | |
| (IISAIIKIZUIIIAD) | | manti Eria ito E. injece | 500111g, 2. 11111 5Q | via injector | at week 12, then every 5 m | seno trierearter | | | |
| | | | | | | | | | |
| Other: | Specify Dosage: | | | | | | | | |
| | | | | | | | . — | | |
| Pre-medication & other meds Acetaminophen 250ml 0.9%NaCl for hydration Flush Protocol | | | | | | | | | |
| * Infusion supplies as per protocol * Infusion supplies as per protocol * NaCl 0.9% NaCl for hydration * NaCl 0.9% 10ml | | | | | | | | | |
| * Anaphylaxis kit as per protocol Diphenhydramine Other mg PO IV * Before & after infusion | | | | | | | | | |
| I authorize Vital Care Infusion Services LLC and its representatives to initiate any insurance prior authorization process Develoian Signature: | | | | | | | | | |
| toutionize vital care infusion services Ltd and its representatives to initiate any insurance prior automoration process that is required for this prescription and for any future refills of the same prescription for the patient listed above which I order. I understand that I can revoke this designation at any time by providing written notice to Vital Care. Date: | | | | | | | | | |
| | | - | | | | | | | |

PRESCRIBER MUST MANUALLY SIGN - STAMP SIGNATURE, SIGNATURE BY OTHER PERSONNEL AND COMPUTER-GENERATED SIGNATURES WILL NOT BE ACCEPTED

The attached document(s) contain confidential information which may be considered to be Protected Health Information and therefore required to be maintained as private and secure under HIPAA. The documents may also contain information which is otherwise considered to be privileged under state and federal laws. This communication is for the intended recipient only. If you are not the intended recipient, or a person responsible for delivering this communication to the intended recipient, you are prohibited from viewing, copying and/or distributing the information contained herein. Unlawful disclosure of the information attached may subject you to monetary penalties and sanctions. If you have received this communication in error, you should notify the sender immediately and thereafter permanently destroy all copies of this document in its entirety.